FDA approves DifGen’s generic fluorometholone ophthalmic suspension 0.1% for steroid-responsive anterior segment inflammation

Editor's Note: This content was generated with the assistance of AI.

The US Food and Drug Administration (FDA) has approved a generic formulation of fluorometholone ophthalmic suspension 0.1% from DifGen Pharmaceuticals for the treatment of steroid-responsive inflammatory conditions of the anterior segment of the eye. According to the company, this represents the second FDA-approved generic version of the complex suspension product.

Fluorometholone is a topical corticosteroid indicated for inflammatory conditions involving the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe when corticosteroid therapy is appropriate.¹ The approval expands the limited generic landscape for this ophthalmic suspension, a dosage form that can present formulation and bioequivalence challenges due to particle size distribution, uniformity, and ocular pharmacokinetics.

Regulatory Overview

DifGen’s fluorometholone ophthalmic suspension 0.1% was approved through the abbreviated new drug application (ANDA) pathway, which requires demonstration of pharmaceutical equivalence and bioequivalence to the reference listed drug (RLD).² In the case of ophthalmic suspensions, establishing therapeutic equivalence may involve physicochemical characterization, in vitro studies, and, where required, clinical endpoint bioequivalence studies, depending on FDA guidance.³

The reference product for fluorometholone ophthalmic suspension 0.1% in the US has historically been marketed under brand names such as FML (fluorometholone ophthalmic suspension).¹ The FDA’s approval indicates that DifGen’s product met regulatory standards for quality, safety, and therapeutic equivalence to the RLD.

Clinical Context: Anterior Segment Inflammation

Topical corticosteroids remain a cornerstone of therapy for steroid-responsive ocular inflammatory conditions, including allergic conjunctivitis, postoperative inflammation, episcleritis, and anterior uveitis.⁴ Fluorometholone is often considered a “soft” steroid with relatively lower intraocular pressure (IOP)-elevating potential compared with more potent agents such as dexamethasone, although clinically meaningful IOP elevations can still occur.⁵

Ocular corticosteroids are associated with known risks, including steroid-induced ocular hypertension, glaucoma, delayed wound healing, and secondary infection.^1,4 As such, prescribing clinicians must balance anti-inflammatory efficacy with safety considerations, particularly in patients requiring prolonged therapy or those with known glaucoma risk factors.

Access to lower-cost generic formulations may influence prescribing patterns, particularly in chronic or recurrent inflammatory conditions where affordability affects adherence.

Drug Background and Mechanism of Action

Fluorometholone is a synthetic glucocorticoid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cytokines and mediators, reducing leukocyte infiltration, and stabilizing cellular membranes.⁴ Like other topical ophthalmic corticosteroids, it modulates gene expression through glucocorticoid receptor activation, decreasing prostaglandin and leukotriene synthesis.

Fluorometholone ophthalmic suspension 0.1% has been available in the US market for decades.¹ Compared with newer agents such as loteprednol etabonate—a retrometabolically designed corticosteroid—fluorometholone is an older molecule but remains widely used because of clinician familiarity and established efficacy.⁶

Therapeutic Landscape

The therapeutic landscape for anterior segment inflammation includes multiple topical corticosteroids, such as prednisolone acetate 1%, dexamethasone 0.1%, loteprednol etabonate (in various concentrations), and fluorometholone.⁴ Selection among agents is influenced by inflammatory severity, desired potency, risk of IOP elevation, dosing frequency, and insurance coverage.

Generic availability can significantly affect cost and formulary placement. Complex ophthalmic suspensions, however, can be more difficult to replicate than simple solutions because ensuring consistent drug distribution with shaking and drop instillation is critical to dose accuracy.

Interpretation and Implications

Although the approval does not represent a novel therapeutic advance, it may have practical implications for clinicians and patients. Increased generic competition may reduce acquisition costs and improve patient access, particularly in ambulatory ophthalmology practices where out-of-pocket expenses can influence adherence.

That said, clinicians should remain vigilant regarding product substitution and ensure that patients are counseled appropriately on shaking suspensions before use. As with all topical corticosteroids, appropriate monitoring for IOP elevation and other steroid-related adverse effects remains necessary.^4,5

Because the approval is based on bioequivalence rather than new clinical efficacy data, no new safety or effectiveness findings beyond those already established for fluorometholone are expected.

Limitations and Next Steps

Publicly available details regarding the specific bioequivalence studies or in vitro characterization supporting this approval were limited at the time of publication. Clinicians seeking additional information may consult the FDA’s Orange Book and future FDA postings for therapeutic equivalence ratings and review summaries.²

Postmarketing pharmacovigilance will remain important to monitor for any unexpected safety signals, although none are anticipated beyond the known class effects of topical corticosteroids.

References

1. DailyMed. Fluorometholone ophthalmic suspension 0.1%—prescribing information. National Library of Medicine. Accessed February 16, 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=fluorometholone%20ophthalmic%20suspension

2. US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Accessed February 16, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

3. US Food and Drug Administration. Bioequivalence recommendations for specific products—ophthalmic products. Accessed February 16, 2026. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development

4. American Academy of Ophthalmology. Preferred Practice Pattern: Uveitis—Anterior. 2019. https://www.aao.org/preferred-practice-pattern/uveitis-anterior-ppp

5. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70(4):482-491. https://jamanetwork.com/journals/jamaophthalmology/article-abstract/626078

6. Bartlett JD, Horwitz B. Retrometabolic corticosteroids in ophthalmology. Surv Ophthalmol. 1993;37(4):235-252. https://doi.org/10.1016/0039-6257(93)90094-7